Cancer Innovation · Published 2026-08-01 · DOI 10.1002/cai2.70072
Jiaxin Liu, Jie Jia, Chong Wang, Zongru Zhou, Zhuoyu Cheng, Ziyi Zhang, Xueyi Jiang, Ziyu Huang, Chunyan Li
ABSTRACT As a leading cause of cancer‐related morbidity and mortality worldwide, non‐small cell lung cancer (NSCLC) is profoundly influenced by innate immune cells (IICs). In addition to serving as key mediators of antimicrobial defense and adaptive immune activation, IICs exert pivotal and multifaceted influences on the initiation, progression, and therapeutic responses of NSCLC. This review integrates current knowledge on the classification, phenotypic plasticity, and functions of IICs, as well as their crosstalk within the tumor microenvironment in NSCLC, summarizes therapeutic strategies targeting IICs, and discusses the existing challenges and future perspectives in NSCLC immunotherapy, to provide theoretical references for the immunotherapy of NSCLC.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →
Liu, J., Jia, J., Wang, C., et al. (2026). Innate Immune Cells in Non‐Small Cell Lung Cancer: Roles in Tumor Progression and Therapeutic Responses. Cancer Innovation. https://doi.org/10.1002/cai2.70072